NAS
LGND icon

Nykredit A/S’s Ligand Pharmaceuticals LGND Stock Holding History

Nykredit A/S’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Buy
+864
New +$204K ﹤0.01% 911

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nykredit A/S's LGND Position: Q2 2026 in Review

Nykredit A/S opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 864 shares worth $273K. The stake represents ﹤0.01% of the portfolio and ranks #911 among its holdings.

317 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Nykredit A/S held 864 shares of Ligand Pharmaceuticals worth $273K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #911 holding.
  • 317 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.